A citation-based method for searching scientific literature

Matthew C Stubbs, Scott A Armstrong. Clin Cancer Res 2007
Times Cited: 14







List of co-cited articles
119 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
T Lapidot, C Sirard, J Vormoor, B Murdoch, T Hoang, J Caceres-Cortes, M Minden, B Paterson, M A Caligiuri, J E Dick. Nature 1994
28

Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
Emmanuelle Passegué, Catriona H M Jamieson, Laurie E Ailles, Irving L Weissman. Proc Natl Acad Sci U S A 2003
460
28

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Andrei V Krivtsov, David Twomey, Zhaohui Feng, Matthew C Stubbs, Yingzi Wang, Joerg Faber, Jason E Levine, Jing Wang, William C Hahn, D Gary Gilliland,[...]. Nature 2006
21



Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.
I D Bernstein, J W Singer, F O Smith, R G Andrews, D A Flowers, J Petersens, L Steinmann, V Najfeld, D Savage, S Fruchtman. Blood 1992
54
21

FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Jessica A Pollard, Todd A Alonzo, Robert B Gerbing, William G Woods, Beverly J Lange, David A Sweetser, Jerald P Radich, Irwin D Bernstein, Soheil Meshinchi. Blood 2006
46
21

Tumour stem cells and drug resistance.
Michael Dean, Tito Fojo, Susan Bates. Nat Rev Cancer 2005
21

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Alan K Burnett, Robert K Hills, Donald Milligan, Lars Kjeldsen, Jonathan Kell, Nigel H Russell, John A L Yin, Ann Hunter, Anthony H Goldstone, Keith Wheatley. J Clin Oncol 2011
463
21


Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Sylvie Castaigne, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Dominique Bordessoule, Jean-Noel Bastie, Ollivier Legrand, Xavier Thomas, Pascal Turlure, Oumedaly Reman,[...]. Lancet 2012
613
21

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.
J D Griffin, D Linch, K Sabbath, P Larcom, S F Schlossman. Leuk Res 1984
424
21

Leukemia stem cells.
Steven W Lane, D Gary Gilliland. Semin Cancer Biol 2010
40
21

The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors.
R G Andrews, M Takahashi, G M Segal, J S Powell, I D Bernstein, J W Singer. Blood 1986
129
21


Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.
I D Bernstein, J W Singer, R G Andrews, A Keating, J S Powell, B H Bjornson, J Cuttner, V Najfeld, G Reaman, W Raskind. J Clin Invest 1987
73
21


Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia.
P J Fialkow, J W Singer, W H Raskind, J W Adamson, R J Jacobson, I D Bernstein, L W Dow, V Najfeld, R Veith. N Engl J Med 1987
311
21


Stem cell gene expression programs influence clinical outcome in human leukemia.
Kolja Eppert, Katsuto Takenaka, Eric R Lechman, Levi Waldron, Björn Nilsson, Peter van Galen, Klaus H Metzeler, Armando Poeppl, Vicki Ling, Joseph Beyene,[...]. Nat Med 2011
678
21

Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
R Lumkul, N-C Gorin, M T Malehorn, G T Hoehn, R Zheng, B Baldwin, D Small, S Gore, D Smith, P S Meltzer,[...]. Leukemia 2002
48
21

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
Brian J P Huntly, Hirokazu Shigematsu, Kenji Deguchi, Benjamin H Lee, Shinichi Mizuno, Nicky Duclos, Rebecca Rowan, Sonia Amaral, David Curley, Ifor R Williams,[...]. Cancer Cell 2004
509
14

Recent advances in cancer stem cells.
Robert W Cho, Michael F Clarke. Curr Opin Genet Dev 2008
171
14

Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct.
K S Gotze, M Ramirez, K Tabor, D Small, W Matthews, C I Civin. Blood 1998
66
14

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Florian Heidel, Fian K Solem, Frank Breitenbuecher, Daniel B Lipka, Stefan Kasper, M H Thiede, Christian Brandts, Hubert Serve, Johannes Roesel, Francis Giles,[...]. Blood 2006
212
14

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer,[...]. Blood 2002
14

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Ellen Weisberg, Christina Boulton, Louise M Kelly, Paul Manley, Doriano Fabbro, Thomas Meyer, D Gary Gilliland, James D Griffin. Cancer Cell 2002
481
14


The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.
James Griffith, James Black, Carlos Faerman, Lora Swenson, Michael Wynn, Fan Lu, Judith Lippke, Kumkum Saxena. Mol Cell 2004
335
14

Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.
C E Carow, M Levenstein, S H Kaufmann, J Chen, S Amin, P Rockwell, L Witte, M J Borowitz, C I Civin, D Small. Blood 1996
235
14

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Keith W Pratz, Jorge Cortes, Gail J Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small,[...]. Blood 2009
140
14

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Rui Zheng, Mark Levis, Obdulio Piloto, Patrick Brown, Brenda R Baldwin, Norbert C Gorin, Miloslav Beran, Zhenping Zhu, Dale Ludwig, Dan Hicklin,[...]. Blood 2004
155
14


Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.
F M Abu-Duhier, A C Goodeve, G A Wilson, R S Care, I R Peake, J T Reilly. Br J Haematol 2001
316
14

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
M Nakao, S Yokota, T Iwai, H Kaneko, S Horiike, K Kashima, Y Sonoda, T Fujimoto, S Misawa. Leukemia 1996
924
14

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Mark Levis, Kathleen M Murphy, Rosalyn Pham, Kyu-Tae Kim, Adam Stine, Li Li, Ian McNiece, B Douglas Smith, Donald Small. Blood 2005
107
14

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
M E Gorre, M Mohammed, K Ellwood, N Hsu, R Paquette, P N Rao, C L Sawyers. Science 2001
14

FLT3: ITDoes matter in leukemia.
M Levis, D Small. Leukemia 2003
354
14

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
B Douglas Smith, Mark Levis, Miloslav Beran, Francis Giles, Hagop Kantarjian, Karin Berg, Kathleen M Murphy, Tianna Dauses, Jeffrey Allebach, Donald Small. Blood 2004
481
14

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
Obdulio Piloto, Melissa Wright, Patrick Brown, Kyu-Tae Kim, Mark Levis, Donald Small. Blood 2007
130
14

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
Steven Knapper, Alan K Burnett, Tim Littlewood, W Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J Levis, Donald Small. Blood 2006
317
14

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Mark Levis, Patrick Brown, B Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel Deangelo, Ilene Galinsky, Frank Giles, Elihu Estey,[...]. Blood 2006
166
14

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
T M Kohl, C Hellinger, F Ahmed, C Buske, W Hiddemann, S K Bohlander, K Spiekermann. Leukemia 2007
80
14

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Y Yamamoto, H Kiyoi, Y Nakano, R Suzuki, Y Kodera, S Miyawaki, N Asou, K Kuriyama, F Yagasaki, C Shimazaki,[...]. Blood 2001
902
14

The roles of FLT3 in hematopoiesis and leukemia.
D Gary Gilliland, James D Griffin. Blood 2002
14

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.
Rui Zheng, Alan D Friedman, Mark Levis, Li Li, Edward G Weir, Donald Small. Blood 2004
129
14

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Weiguo Zhang, Marina Konopleva, Yue-xi Shi, Teresa McQueen, David Harris, Xiaoyang Ling, Zeev Estrov, Alfonso Quintás-Cardama, Donald Small, Jorge Cortes,[...]. J Natl Cancer Inst 2008
285
14

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Jan Cools, Nicole Mentens, Pascal Furet, Doriano Fabbro, Jennifer J Clark, James D Griffin, Peter Marynen, D Gary Gilliland. Cancer Res 2004
144
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.